Rnase l-mediated cleavage products and uses thereof
AssigneeThe Cleveland Clinic Foundation
InventorsRobert H. Silverman, Malathi Krishnamurthy
Life of this patent
Estimating the term…
Abstract
The invention is directed to one or more RNase L mediated cleavage products. In particular aspects, the RNase L mediated cleavage products are RNase L mediated cleavage products of a virus, referred to herein as a “suppressor of virus ribonucleic acid (RNA)” or “svRNA” and uses thereof.
Claims25
An isolated nucleic acid sequence comprising SEQ ID NO:
- 1.
An isolated nucleic acid sequence comprising SEQ ID NO:
- 25.
An isolated nucleic acid sequence comprising SEQ ID NO:
- 26.
A method of inducing an immune response to a hepatitis C virus (HCV) in a cell comprising introducing into the cell a composition comprising a HCV svRNA;
- and maintaining the cell under conditions in which the svRNA stimulates RIG-1 signaling and propagates signaling to the IFN-β gene, thereby inducing an immune to the HCV in the cell.
A method of inducing an immune response to HCV in an individual in need thereof comprising administering a therapeutically effective amount of a composition comprising a HCV svRNA that stimulates RIG-1 signaling and propagates signaling to the IFN-β gene, thereby inducing an immune response to the HCV in the individual.
A method of treating a HCV in an individual in need thereof comprising administering a therapeutically effective amount of a composition comprising a HCV svRNA (e.g., HCV svRNA3) that stimulates RIG-1 signaling and propagates signaling to the IFN-β gene, thereby inducing an immune response to the HCV in the individual.
Dependencies are inferred from the claim text.